A study has found that two years after biosimilars became available in the U.S., a higher proportion of patients using brand-name biologics were paying out-of-pocket costs, which were also, on average, 12% higher than before. In addition, patients who used biosimilars often did not pay lower out-of-pocket costs than those who were given brand-name biologic medicines. The findings suggest that the arrival of biosimilars has failed to fully deliver on their promise of lower costs for patients.